Cytokinetics is preparing a global Phase 3 trial that will enroll more than 500 people with early amyotrophic lateral sclerosis (ALS) to test its investigational therapy reldesemtiv in slowing progressive muscle weakness, the company announced
- Welcome to the MND Association Forum.
If this is your first visit, be sure to check out the Forum Guidelines. You will need to Register before you can post. All registrations are manually approved by the Forum Admin team to try and help prevent spam so there may be a slight delay between registering and being able to post.
To start viewing posts, select the section of the forum that you want to visit from the selection below.